Relmada Therapeutics Appoints Distinguished Urologic Oncologist Max Kates, MD, To Clinical Advisory Board To Support NDV-01 Development

Relmada Therapeutics, Inc., a clinical-stage biotechnology company focused on developing innovative therapies for oncology and central nervous system disorders, has announced the appointment of Max Kates, MD, Associate Professor of Urology and Oncology at Johns Hopkins University School of Medicine, to its Clinical Advisory Board. Dr. Kates will provide guidance on the development of NDV-01, a potential treatment for non-muscle invasive bladder cancer (NMIBC), as Relmada prepares to initiate a Phase 3 clinical program in the first half of 2026.

Dr. Raj Pruthi, Chief Medical Officer for Urology at Relmada, highlighted the significance of Dr. Kates’ appointment. He stated that with preparations for the Phase 3 program underway, Dr. Kates’ extensive experience in chairing the landmark Phase 3 BRIDGE trial, along with his leadership in other influential studies, brings a unique clinical perspective that will be invaluable for the design and execution of the NDV-01 program. Dr. Pruthi also noted that Dr. Kates’ deep understanding of the operational complexities in high-volume urologic oncology practices will help ensure the program is designed with real-world applicability in mind.

Dr. Kates commented on his new role, expressing optimism about NDV-01’s potential to improve NMIBC treatment. He noted that his experience leading the international Phase 3 BRIDGE study provided him with insight into the clinical community’s enthusiasm for intravesical delivery of gemcitabine and docetaxel as a bladder-sparing approach. He highlighted that the initial safety and efficacy data for NDV-01, presented at the American Urologic Association in April 2025 and updated in August, support the potential benefits of a sustained-release formulation of “Gem/Doce” for both patients and clinical practices. Dr. Kates stated, “I believe NDV-01 has the potential to transform the treatment of NMIBC, and I am pleased to join the Relmada Clinical Advisory Board, where I look forward to contributing my expertise to the pivotal program.”

Through this appointment, Relmada strengthens its Clinical Advisory Board with a leading urologic oncology expert, positioning the company to advance NDV-01 toward its Phase 3 program and ultimately address a significant unmet need in bladder cancer care.